文献速递新发突发、热带与寄生虫病

V181与Butantan-DV四价登革热减毒活疫苗在巴西健康成人中的安全性和免疫原性比较:一项随机双盲2期试验

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该随机双盲2期试验在巴西健康成人中比较V181与Butantan-DV两种单剂四价登革热减毒活疫苗的安全性和免疫原性,共纳入1364人按1:1分组。接种后第28天,V181对DENV-1和DENV-2的中和抗体GMT非劣效于Butantan-DV,但对DENV-3和DENV-4未达非劣效;所有血清型的血清转化率均非劣效。两者总体耐受良好,V181安全性特征与Butantan-DV相当。

要点

  • V181对DENV-1和DENV-2的GMT非劣效于Butantan-DV,DENV-3和DENV-4未达非劣效。
  • 基于血清转化率,V181对全部四种DENV血清型均非劣效于Butantan-DV。
  • V181与Butantan-DV总体耐受良好,安全性特征相当。

核心结论

  • V181在成人中具有免疫原性,对DENV-1和DENV-2的GMT非劣效于Butantan-DV,对DENV-1至DENV-4的血清转化率非劣效。
  • V181安全性特征与Butantan-DV相当,支持其作为单剂四价登革热疫苗继续评估。

研究设计与样本

  • 随机、双盲、阳性对照、多中心2期试验,在巴西健康成人中比较V181与Butantan-DV。
  • 共1364名参与者按1:1分配至V181组(n=682)或Butantan-DV组(n=682)。
  • 主要免疫原性目标为比较接种后第28天DENV-1至DENV-4中和抗体GMT和血清转化率。
  • 主要和次要安全性目标分别为评估疫苗相关严重不良事件和至接种后第28天征集性不良事件比例。

主要发现

  • 接种后第28天,基于GMT比值,V181对DENV-1和DENV-2的免疫应答非劣效于Butantan-DV,但对DENV-3和DENV-4未达非劣效。
  • 基于血清转化率,V181对全部DENV血清型均非劣效于Butantan-DV。
  • 大多数参与者产生三价或四价中和抗体应答。
  • 各DENV血清型均检测到疫苗病毒血症。
  • V181与Butantan-DV总体耐受良好。

关键数值与推荐

  • 主要免疫原性比较:接种后第28天DENV-1至DENV-4中和抗体GMT比值和血清转化率。
  • 非劣效性:V181对DENV-1和DENV-2的GMT非劣效于Butantan-DV;对DENV-3和DENV-4的GMT未达非劣效。
  • 非劣效性:V181对DENV-1至DENV-4的血清转化率均非劣效于Butantan-DV。

临床怎么用

  • V181作为单剂四价登革热疫苗在健康成人中显示免疫原性和与Butantan-DV相当的安全性,支持继续评估。
  • 对DENV-3和DENV-4的GMT非劣效性未确立,需在后续研究中进一步评估其四价保护覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dengue is caused by infection with 1 of 4 dengue virus (DENV) serotypes (DENV-1 to DENV-4). V181 and Butantan-Dengue Vaccine (Butantan-DV) are independently developed, single-dose, quadrivalent dengue vaccines based on the same attenuated parental strains. METHODS: In this randomized, double-blind, active comparator-controlled, multisite, phase 2 trial, we compared the safety and immunogenicity of V181 and Butantan-DV in healthy adults in Brazil. The primary immunogenicity objectives were to compare vaccine-induced neutralizing antibody geometric mean titers (GMTs) and seroconversion rates for DENV-1 to DENV-4 at day 28 postvaccination. The primary and secondary safety objectives, respectively, were to assess vaccine-related serious adverse events and the proportion of participants experiencing solicited adverse events through day 28 postvaccination. RESULTS: Overall, 1364 participants were assigned (1:1) to receive V181 (n = 682) or Butantan-DV (n = 682). At day 28 postvaccination, V181 induced a noninferior immune response to Butantan-DV for DENV-1 and DENV-2 but not DENV-3 and DENV-4, as measured using GMT ratios. Noninferiority was established for all DENV serotypes based on seroconversion rates. Most participants developed a trivalent or tetravalent neutralizing antibody response. Vaccine viremia was detected for each DENV serotype. V181 and Butantan-DV were generally well tolerated. CONCLUSIONS: V181 was immunogenic in adults, and while immunogenicity was noninferior to Butantan-DV for DENV-1 and DENV-2, seroconversion rates were noninferior for DENV-1 to DENV-4. The safety profile of V181 is comparable to that of Butantan-DV and supports its continued evaluation as a single-dose quadrivalent vaccine for dengue prevention. CLINICAL TRIALS REGISTRATION: NCT05710224.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Alexanderian D, Ramos F, Chatterjee S, et al. Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial. Clin Infect Dis. 2026. PMID: 42383822. doi:10.1093/cid/ciag349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。